Clinical trial • Phase I • Oncology
JNJ-95566692 for Non-Hodgkin lymphoma | Diffuse large B-cell lymphoma
Phase I trial of JNJ-95566692 for Non-Hodgkin lymphoma | Diffuse large B-cell lymphoma. 71 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Non-Hodgkin lymphoma | Diffuse large B-cell lymphoma
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 08-01-2026
- First CTIS Authorization Date
- 26-02-2026
Trial design
Phase I trial across 2 sites in Belgium.
- Target Sample Size
- 71
Recruitment
- Planned Sample Size
- 71
- Recruitment Window Months
- 29
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 71
Belgium
- Earliest CTIS Part Ii Submission Date
- 16-02-2026
- Latest Decision Or Authorization Date
- 26-02-2026
- Processing Time Days
- 10
- Number Of Sites
- 2
- Number Of Participants
- 13
Sites
- Site Name
- Universitair Ziekenhuis Antwerpen
- Department Name
- Hematology
- Contact Person Name
- Sebastien Anguille
- Contact Person Email
- Sebastien.anguille@uza.be
- Site Name
- Centre hospitalier universitaire de Liege
- Department Name
- Hematology
- Contact Person Name
- Claire Maquet
- Contact Person Email
- cmaquet@chuliege.be
Sponsor
Primary sponsor
- Full Name
- Janssen Cilag International
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Belgium
Investigational products
- Investigational Product Name
- JNJ-95566692
- First In Human
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)